SILK ROAD MEDICAL, INC Financials Silk Road Medical, Inc
Equities
SILK
US82710M1009
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.9 USD | +6.18% |
|
+8.56% | +54.03% |
| Apr. 02 | Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus | CI |
| Mar. 08 | North American Morning Briefing : Stock Futures -2- | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,246 | 2,139 | 1,487 | 2,015 | 477.9 | 745.5 | - | - |
| Enterprise Value (EV) 1 | 1,201 | 2,118 | 1,425 | 1,876 | 372 | 736.2 | 706.7 | 694 |
| P/E ratio | -17.7 x | -43.7 x | -29.6 x | -34.3 x | -8.52 x | -13.8 x | -14.9 x | -16.6 x |
| Yield | - | - | - | - | - | 0.68% | - | - |
| Capitalization / Revenue | 19.7 x | 28.4 x | 14.7 x | 14.5 x | 2.7 x | 3.81 x | 3.44 x | 3.13 x |
| EV / Revenue | 18.9 x | 28.2 x | 14 x | 13.5 x | 2.1 x | 3.76 x | 3.26 x | 2.91 x |
| EV / EBITDA | -43.9 x | -51.1 x | -30.7 x | -37.6 x | -6.58 x | -13 x | -14.2 x | -16 x |
| EV / FCF | -39.8 x | -49.4 x | -32.6 x | -49.9 x | -11.1 x | -46 x | -64.2 x | -99.1 x |
| FCF Yield | -2.51% | -2.03% | -3.07% | -2% | -9.01% | -2.17% | -1.56% | -1.01% |
| Price to Book | 12.9 x | 19.3 x | 18.6 x | 12.4 x | 3.15 x | 5.4 x | 5.82 x | 6.04 x |
| Nbr of stocks (in thousands) | 30,866 | 33,959 | 34,896 | 38,123 | 38,945 | 39,442 | - | - |
| Reference price 2 | 40.38 | 62.98 | 42.61 | 52.85 | 12.27 | 18.90 | 18.90 | 18.90 |
| Announcement Date | 2/26/20 | 3/1/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 63.35 | 75.23 | 101.5 | 138.6 | 177.1 | 195.7 | 216.9 | 238.4 |
| EBITDA 1 | -27.35 | -41.47 | -46.44 | -49.88 | -56.58 | -56.56 | -49.93 | -43.4 |
| EBIT 1 | -28.06 | -42.86 | -47.47 | -52 | -59.27 | -57.88 | -52.75 | -46.68 |
| Operating Margin | -44.3% | -56.97% | -46.78% | -37.51% | -33.46% | -29.57% | -24.32% | -19.58% |
| Earnings before Tax (EBT) 1 | -52.42 | -47.36 | -49.81 | -55.01 | -55.74 | -54.41 | -50.43 | -45.74 |
| Net income 1 | -52.42 | -47.36 | -49.81 | -55.01 | -55.74 | -54.21 | -50.25 | -45.74 |
| Net margin | -82.73% | -62.96% | -49.09% | -39.68% | -31.47% | -27.7% | -23.17% | -19.18% |
| EPS 2 | -2.280 | -1.440 | -1.440 | -1.540 | -1.440 | -1.368 | -1.270 | -1.137 |
| Free Cash Flow 1 | -30.14 | -42.91 | -43.69 | -37.59 | -33.52 | -16 | -11 | -7 |
| FCF margin | -47.58% | -57.04% | -43.06% | -27.11% | -18.92% | -8.17% | -5.07% | -2.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | 0.1280 | - | - |
| Announcement Date | 2/26/20 | 3/1/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24.7 | 28.26 | 28.02 | 33.17 | 37.37 | 40.07 | 40.13 | 45.3 | 44.44 | 47.27 | 44.69 | 48.95 | 49.35 | 52.85 | 50.45 |
| EBITDA 1 | -13.05 | -13.75 | -15.53 | -13.69 | -8.683 | -11.97 | -16.21 | -13.63 | -13.02 | -13.72 | -15.83 | -14.39 | -13.67 | -12.67 | -12 |
| EBIT 1 | -13.29 | -14.06 | -15.95 | -14.19 | -9.226 | -12.63 | -16.91 | -14.32 | -13.67 | -14.37 | -16.62 | -15.02 | -14.03 | -12.55 | -13.98 |
| Operating Margin | -53.81% | -49.75% | -56.94% | -42.79% | -24.69% | -31.52% | -42.14% | -31.6% | -30.77% | -30.4% | -37.2% | -30.68% | -28.43% | -23.74% | -27.71% |
| Earnings before Tax (EBT) 1 | -13.88 | -14.69 | -16.68 | -15.4 | -10.32 | -12.61 | -16.46 | -13.48 | -12.79 | -13.01 | -15.83 | -13.88 | -12.98 | -11.81 | -14.18 |
| Net income 1 | -13.88 | -14.69 | -16.68 | -15.4 | -10.32 | -12.61 | -16.46 | -13.48 | -12.79 | -13.01 | -15.7 | -13.92 | -12.83 | -11.64 | -14.18 |
| Net margin | -56.21% | -51.98% | -59.52% | -46.42% | -27.61% | -31.48% | -41.02% | -29.77% | -28.78% | -27.52% | -35.12% | -28.45% | -25.99% | -22.03% | -28.1% |
| EPS 2 | -0.4000 | -0.4200 | -0.4800 | -0.4400 | -0.2900 | -0.3400 | -0.4300 | -0.3500 | -0.3300 | -0.3300 | -0.4044 | -0.3548 | -0.3313 | -0.2954 | -0.3700 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/24/22 | 5/4/22 | 7/26/22 | 11/8/22 | 2/28/23 | 5/9/23 | 8/1/23 | 11/8/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 45.8 | 20.9 | 61.5 | 139 | 106 | 9.23 | 38.8 | 51.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -30.1 | -42.9 | -43.7 | -37.6 | -33.5 | -16 | -11 | -7 |
| ROE (net income / shareholders' equity) | -179% | -52.8% | -53.3% | -45.3% | -35.4% | -37.7% | -37.5% | -41% |
| ROA (Net income/ Total Assets) | -58.2% | -29.9% | -29.7% | -25.8% | -20.8% | -21% | -21.3% | -21.4% |
| Assets 1 | 90.07 | 158.4 | 168 | 213.2 | 267.5 | 258.6 | 235.6 | 213.5 |
| Book Value Per Share 2 | 3.130 | 3.260 | 2.290 | 4.270 | 3.900 | 3.500 | 3.250 | 3.130 |
| Cash Flow per Share 2 | -1.290 | -1.280 | - | -0.9100 | -0.8300 | -0.4500 | -0.3000 | - |
| Capex 1 | 0.54 | 0.84 | 4.76 | 5.01 | 1.51 | 2 | 3.4 | 3.6 |
| Capex / Sales | 0.84% | 1.12% | 4.69% | 3.61% | 0.85% | 1.02% | 1.57% | 1.51% |
| Announcement Date | 2/26/20 | 3/1/21 | 2/24/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
18.9
USD
Average target price
18.43
USD
Spread / Average Target
-2.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +54.03% | 745M | |
| -2.54% | 186B | |
| -1.85% | 107B | |
| -4.26% | 67.44B | |
| +1.39% | 50.03B | |
| +16.82% | 47.81B | |
| +4.79% | 41.03B | |
| +3.49% | 26.85B | |
| +0.65% | 25.82B | |
| +16.55% | 24.74B |
- Stock Market
- Equities
- SILK Stock
- Financials Silk Road Medical, Inc
